125 related articles for article (PubMed ID: 38759016)
1. Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review.
Kurihara M; Kondo S; Ohse K; Nojima H; Kikkawa-Saito E; Iwata A
J Alzheimers Dis; 2024; 99(3):1077-1092. PubMed ID: 38759016
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
[TBL] [Abstract][Full Text] [Related]
3. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis.
Agnello L; Piccoli T; Vidali M; Cuffaro L; Lo Sasso B; Iacolino G; Giglio VR; Lupo F; Alongi P; Bivona G; Ciaccio M
Scand J Clin Lab Invest; 2020 Jul; 80(4):313-317. PubMed ID: 32255379
[TBL] [Abstract][Full Text] [Related]
6. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J
Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
8. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
[TBL] [Abstract][Full Text] [Related]
9. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.
Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I
Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform.
Martínez-Dubarbie F; Guerra-Ruiz A; López-García S; Lage C; Fernández-Matarrubia M; Infante J; Pozueta-Cantudo A; García-Martínez M; Corrales-Pardo A; Bravo M; López-Hoyos M; Irure-Ventura J; Sánchez-Juan P; García-Unzueta MT; Rodríguez-Rodríguez E
Alzheimers Res Ther; 2023 Oct; 15(1):163. PubMed ID: 37784138
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer's Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms.
Dakterzada F; Cipriani R; López-Ortega R; Arias A; Riba-Llena I; Ruiz-Julián M; Huerto R; Tahan N; Matute C; Capetillo-Zarate E; Piñol-Ripoll G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731812
[TBL] [Abstract][Full Text] [Related]
12. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid.
Gobom J; Parnetti L; Rosa-Neto P; Vyhnalek M; Gauthier S; Cataldi S; Lerch O; Laczo J; Cechova K; Clarin M; Benet AL; Pascoal TA; Rahmouni N; Vandijck M; Huyck E; Le Bastard N; Stevenson J; Chamoun M; Alcolea D; Lleó A; Andreasson U; Verbeek MM; Bellomo G; Rinaldi R; Ashton NJ; Zetterberg H; Sheardova K; Hort J; Blennow K
Clin Chem Lab Med; 2022 Jan; 60(2):207-219. PubMed ID: 34773730
[TBL] [Abstract][Full Text] [Related]
13. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
15. Concordance of Alzheimer's Disease-Related Biomarkers Between Intraventricular and Lumbar Cerebrospinal Fluid in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Vanninen A; Tesseur I; Pemberton D; Van Der Ark P; Kokkola T; Herukka SK; Rauramaa T; Hiltunen M; Blennow K; Zetterberg H; Leinonen V
J Alzheimers Dis; 2023; 91(1):305-319. PubMed ID: 36404546
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
17. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
18. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
[TBL] [Abstract][Full Text] [Related]
19. Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort.
Orellana A; García-González P; Valero S; Montrreal L; de Rojas I; Hernández I; Rosende-Roca M; Vargas L; Tartari JP; Esteban-De Antonio E; Bojaryn U; Narvaiza L; Alarcón-Martín E; Alegret M; Alcolea D; Lleó A; Tárraga L; Pytel V; Cano A; Marquié M; Boada M; Ruiz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805894
[TBL] [Abstract][Full Text] [Related]
20. Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease.
Wang LS; Leung YY; Chang SK; Leight S; Knapik-Czajka M; Baek Y; Shaw LM; Lee VM; Trojanowski JQ; Clark CM
J Alzheimers Dis; 2012; 31(2):439-45. PubMed ID: 22571982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
